Cargando…
Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC)
PURPOSE: Tuberous sclerosis complex (TSC)-associated renal angiomyolipoma (AML) have a high lifetime risk of acute bleeding. MTOR-inhibitors are a promising novel treatment for TSC-AML, however adequate response to therapy can be difficult to assess. Early changes in MRI signal may serve as a novel...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726644/ https://www.ncbi.nlm.nih.gov/pubmed/29232371 http://dx.doi.org/10.1371/journal.pone.0189132 |
_version_ | 1783285732468588544 |
---|---|
author | Brakemeier, Susanne Vogt, Lars Adams, Lisa Zukunft, Bianca Diederichs, Gerd Hamm, Bernd Budde, Klemens Makowski, Marcus R. |
author_facet | Brakemeier, Susanne Vogt, Lars Adams, Lisa Zukunft, Bianca Diederichs, Gerd Hamm, Bernd Budde, Klemens Makowski, Marcus R. |
author_sort | Brakemeier, Susanne |
collection | PubMed |
description | PURPOSE: Tuberous sclerosis complex (TSC)-associated renal angiomyolipoma (AML) have a high lifetime risk of acute bleeding. MTOR-inhibitors are a promising novel treatment for TSC-AML, however adequate response to therapy can be difficult to assess. Early changes in MRI signal may serve as a novel early indicator for a satisfactory response to mTOR-inhibitor therapy of AML. MATERIALS AND METHODS: Thirty-eight patients with the definite diagnosis of tuberous sclerosis receiving everolimus therapy and n = 19 patients without specific therapy were included. 1.5 Tesla MRI was performed including sequences with a selective fat suppression. Patients were investigated prior to the initiation of therapy (baseline) and after <3 months (n = 21 patients), 3 to 6 months (n = 32) and 18 to 24 months (n = 28). Signal and size changes of renal AMLs were assessed at all different timepoints. Signal-to-noise-ratio (SNR), contrast-to-noise-ratio (CNR) and size of angiomyolipomas were evaluated. RESULTS: Signal changes in 273 AMLs were evaluated. A significant and strong decrease of the CNR of AMLs following the initiation of therapy was measured in the fat-suppressed MR sequence at all time points, compared to the baseline: From 7.41±6.98 to 3.84±6.25 (p ≤ 0.05p = 0.002), 3.36±6.93 (p<0.0001), and 2.50±6.68 (p<0.0001) after less than 3 months, 3–6 months or 18–24 months of everolimus treatment, respectively. Also, a significant, however less pronounced, reduction of angiomyolipoma size in the different groups was measured (from baseline 2022.2±2657.7 mm2 to 1854.4±1670.9 mm2 (p = 0.009), 1875.5±3190.1 mm2 (p<0.001), and 1365.8 ± 1628.8 mm2 (p<0.0001) after less than 3 months, 3–6 months or 18–24 months of everolimus treatment, respectively). No significant changes in CNR (p>0.05) and size (p>0.05) were measured in the control group. CONCLUSION: mTOR inhibitor therapy in TSC patients results in an early and pronounced fatty transformation of AMLs on MRI. Fatty transformation could represent a novel early indicator of response to therapy in this patient collective. |
format | Online Article Text |
id | pubmed-5726644 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-57266442017-12-22 Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC) Brakemeier, Susanne Vogt, Lars Adams, Lisa Zukunft, Bianca Diederichs, Gerd Hamm, Bernd Budde, Klemens Makowski, Marcus R. PLoS One Research Article PURPOSE: Tuberous sclerosis complex (TSC)-associated renal angiomyolipoma (AML) have a high lifetime risk of acute bleeding. MTOR-inhibitors are a promising novel treatment for TSC-AML, however adequate response to therapy can be difficult to assess. Early changes in MRI signal may serve as a novel early indicator for a satisfactory response to mTOR-inhibitor therapy of AML. MATERIALS AND METHODS: Thirty-eight patients with the definite diagnosis of tuberous sclerosis receiving everolimus therapy and n = 19 patients without specific therapy were included. 1.5 Tesla MRI was performed including sequences with a selective fat suppression. Patients were investigated prior to the initiation of therapy (baseline) and after <3 months (n = 21 patients), 3 to 6 months (n = 32) and 18 to 24 months (n = 28). Signal and size changes of renal AMLs were assessed at all different timepoints. Signal-to-noise-ratio (SNR), contrast-to-noise-ratio (CNR) and size of angiomyolipomas were evaluated. RESULTS: Signal changes in 273 AMLs were evaluated. A significant and strong decrease of the CNR of AMLs following the initiation of therapy was measured in the fat-suppressed MR sequence at all time points, compared to the baseline: From 7.41±6.98 to 3.84±6.25 (p ≤ 0.05p = 0.002), 3.36±6.93 (p<0.0001), and 2.50±6.68 (p<0.0001) after less than 3 months, 3–6 months or 18–24 months of everolimus treatment, respectively. Also, a significant, however less pronounced, reduction of angiomyolipoma size in the different groups was measured (from baseline 2022.2±2657.7 mm2 to 1854.4±1670.9 mm2 (p = 0.009), 1875.5±3190.1 mm2 (p<0.001), and 1365.8 ± 1628.8 mm2 (p<0.0001) after less than 3 months, 3–6 months or 18–24 months of everolimus treatment, respectively). No significant changes in CNR (p>0.05) and size (p>0.05) were measured in the control group. CONCLUSION: mTOR inhibitor therapy in TSC patients results in an early and pronounced fatty transformation of AMLs on MRI. Fatty transformation could represent a novel early indicator of response to therapy in this patient collective. Public Library of Science 2017-12-12 /pmc/articles/PMC5726644/ /pubmed/29232371 http://dx.doi.org/10.1371/journal.pone.0189132 Text en © 2017 Brakemeier et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Brakemeier, Susanne Vogt, Lars Adams, Lisa Zukunft, Bianca Diederichs, Gerd Hamm, Bernd Budde, Klemens Makowski, Marcus R. Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC) |
title | Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC) |
title_full | Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC) |
title_fullStr | Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC) |
title_full_unstemmed | Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC) |
title_short | Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC) |
title_sort | treatment effect of mtor-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (tsc) |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726644/ https://www.ncbi.nlm.nih.gov/pubmed/29232371 http://dx.doi.org/10.1371/journal.pone.0189132 |
work_keys_str_mv | AT brakemeiersusanne treatmenteffectofmtorinhibitionontissuecompositionofrenalangiomyolipomasintuberoussclerosiscomplextsc AT vogtlars treatmenteffectofmtorinhibitionontissuecompositionofrenalangiomyolipomasintuberoussclerosiscomplextsc AT adamslisa treatmenteffectofmtorinhibitionontissuecompositionofrenalangiomyolipomasintuberoussclerosiscomplextsc AT zukunftbianca treatmenteffectofmtorinhibitionontissuecompositionofrenalangiomyolipomasintuberoussclerosiscomplextsc AT diederichsgerd treatmenteffectofmtorinhibitionontissuecompositionofrenalangiomyolipomasintuberoussclerosiscomplextsc AT hammbernd treatmenteffectofmtorinhibitionontissuecompositionofrenalangiomyolipomasintuberoussclerosiscomplextsc AT buddeklemens treatmenteffectofmtorinhibitionontissuecompositionofrenalangiomyolipomasintuberoussclerosiscomplextsc AT makowskimarcusr treatmenteffectofmtorinhibitionontissuecompositionofrenalangiomyolipomasintuberoussclerosiscomplextsc |